Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer

Cancer and Metastasis Reviews

Volumn 25, Issue 3, 2006, Pages 323-331

  Kusmartsev, Sergei ^a   Gabrilovich, Dmitry I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cytokines; Growth factors; Immune suppression; Myeloid cells; Tumor immunology

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; GANGLIOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; JANUS KINASE; PROSTAGLANDIN; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL CELL; BONE MARROW CELL; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; HUMANS; JANUS KINASES; MACROPHAGES; MICE; MYELOID CELLS; NEOPLASMS; STAT TRANSCRIPTION FACTORS; TUMOR ESCAPE;

EID: 33845534522     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-006-9002-6     Document Type: Review

References (68)

1. Kusmartsev, S., Li, Y., & Chen, S.-H. (2000). Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. Journal of Immunology, 165, 779-785.
2. Melani, C., Chiodoni, C., Forni, G., & Colombo, M. P. (2003). Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood, 102, 2138-2145.
3. Kusmartsev, S., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E., & Lush, R., et al. (2003). All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research, 63, 4441-4449.
4. Salvadori, S., Martinelli, G., & Zier, K. (2000). Resection of solid tumors reverses T cell defects and restores protective immunity. Journal of Immunology, 164, 2214.
5. Young, M. R. I., Newby, M., & Wepsic, T. H. (1987). Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Research, 47, 100-106.
6. Subiza, J., Vinuela, J., Rodriguez, R., & De la Concha, E. (1989). Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice. International Journal of Cancer, 44, 307-314.
7. Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., & Zamboni, P., et al. (2000). Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood, 96, 3838.
8. Li, Q., Pan, P. Y., Gu, P., Xu, D., & Chen, S. H. (2004). Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Research, 64, 1130-1139.
9. Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., & Saito, T. (1996). Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 93, 13119-13124.
10. Gabrilovich, D. I., Velders, M., Sotomayor, E., & Kast, W. M. (2001). Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. Journal of Immunology, 166, 5398-5406.
11. Bronte, V., Serafini, P., De Santo, C., Marigo, I., Tosello, V., & Mazzoni, A., et al. (2003). IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. Journal of Immunology, 170, 270-278.
12. Almand, B., Clark, J. I., Nikitina, E., English, N. R., Knight, S. C., & Carbone, D. P., et al. (2001). Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. Journal of Immunology, 166, 678-689.
13. Almand, B., Resser, J., Lindman, B., Nadaf, S., Clark, J., & Kwon, E., et al. (2000). Clinical significance of defective dendritic cell differentiation in cancer. Clinical Cancer Research, 6, 1755-1766.
14. Bronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M., & Hwu, P., et al. (1999). Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. Journal of Immunology, 162, 5728-5737.
15. Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., & Salup, R., et al. (2004). Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. Journal of Immunology, 172, 464-474.
16. Kusmartsev, S., & Gabrilovich, D. I. (2003). Inhibition of myeloid cell differentiation in cancer: The role of reactive oxygen species. Journal of Leukocyte Biology, 74, 186-196.
17. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, T., Meny, G. M., & Nadaf, S., et al. (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine, 2, 1096-1103.
18. Kusmartsev, S., & Gabrilovich, D. (2005). STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. Journal of Immunology, 174, 4880-4891.
19. Toi, M., Kondo, S., Suzuki, H., Yamamoto, Y., Inada, K., & Imazawa, T., et al. (1996). Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer, 77, 1101-1106.
20. Saito, H., Tsujitani, S., Ikeguchi, M., Maeta, M., & Kaibara, N. (1998). Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric carcinoma tissue. British Journal of Cancer, 78, 1573.
21. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., & Nadaf, S., et al. (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92, 4150-4166.
22. Ohm, J. E., Shurin, M. R., Esche, C., Lotze, M. T., & Carbone, D. P., et al. (1999). Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. Journal of Immunology, 163, 3260-3268.
23. Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J., & Carbone, D. P. (1998). Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clinical Cancer Research, 5, 2963-2970.
24. Ishida, T., Oyama, T., Carbone, D., & Gabrilovich, D. I. (1998). Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors. Journal of Immunology, 161, 4842-4851.
25. Dikov, M., Ohm, J., Ray, N., Tchekneva, E., Burlison, J., & Moghanaki, D., et al. (2005). Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. Journal of Immunology, 174, 215-222.
26. Takahashi, A., Kono, K., Ichihara, F., Sugai, H., Fujii, H., & Matsumoto, Y. (2004). Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother, 53, 543-550.
27. Serafini, P., Carbley, R., Noonan, K. A., Tan, G., Bronte, V., & Borrello, I. (2004). High-dose GM-CSF-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Research, 64, 6337-6343.
28. Young, M. R., & Lathers, D. M. (1999). Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. International Journal of Immunopharmacology, 21, 241-252.
29. Fu, Y., Watson, G., Jimenez, J., Wang, Y., & Lopez, D. (1990). Expansion of immunoregulatory macrophages by granulocyte-macrophage colonystimulating factor derived from a murine mammary tumor. Cancer Research, 50, 227.
30. Young, M., Wright, M., & Young, M. (1991). Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells. Cancer Immunol Immunother, 33, 146.
31. Dranoff, G. (2003). GM-CSF-secreting melanoma vaccines. Oncogene, 22, 3188-3192.
32. Seo, N., Hayakawa, S., Takigawa, M., & Tokura, Y. (2001). Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology, 103, 449-457.
33. Yang, A. S., & Lattime, E. C. (2003). Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Research, 63, 2150-2157.
34. Steinbrink, K., Wolfl, M., Jonuleit, H., Knop, J., & Enk, A. H. (1997). Induction of tolerance by IL-10-treated dendritic cells. Journal of Immunology, 159, 4772-4780.
35. Sharma, S., Stolina, M., Lin, Y., Gardner, B., Miller, P., & Kronenberg, M., et al. (1999). T-cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. Journal of Immunology, 163, 5020.
36. Steinbrink, K., Graulich, E., Kubsch, S., Knop, J., & Enk, A. (2002). CD4(+) and CD8(+) anergy T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood, 99, 2468-2476.
37. Allavena, P., Piemonti, L., Longoni, D., Bernasconi, S., Stoppaciaro, A., & Ruco, L., et al. (1998). IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. European Journal of Immunology, 28, 359-363.
38. Mullins, D., Martins, R., Burger, C., & Elgert, K. (2001). Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation. Journal of Leukocyte Biology, 69, 129-137.
39. Harizi, H., Juzan, M., Pitard, V., Moreau, J., & Gualde, N. (2002). Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. Journal of Immunology, 68, 2255-2263.
40. Enk, A. H., Angeloni, V. L., Udey, M. C., & Katz, S. I. (1993). Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. Journal of Immunology, 151, 2390-2398.
41. Peguet Navarro, J., Moulon, C., Caux, C., Dalbiez-Gauthier, C., Banchereau, J., & Schmitt, D. (1994). Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. European Journal of Immunology, 24, 884-889.
42. Beissert, S., Hosoi, J., Grabbe, S., Asahina, A., & Granstein, R. D. (1995). IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. Journal of Immunology, 154, 1280-1286.
43. Caux, C., Massacrier, C., Vanbervliet, B., Barthelemy, C., Liu, Y. J., & Banchereau, J. (1994). Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Intern. Immunol., 6, 1177-1185.
44. Berman, R. M., Suzuki, T., Tahara, H., Robbins, P. D., Narula, S. K., & Lotze, M. T. (1996). Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. Journal of Immunology, 157, 231-238.
45. Menetrier-Caux, C., Montmain, G., Dieu, M., Bain, C., Favrot, M., & Caux, C., et al. (1998). Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage-colony-stimulating factor. Blood, 92, 4778.
46. Menetrier-Caux, C., Thomachot, M. C., Alberti, L., Montmain, G., & Blay, J. Y. (2001). IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Research, 61, 3096-3104.
47. Park, S. J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., & Sawa, S., et al. (2004). IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. Journal of Immunology, 173, 3844-3854.
48. Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., & Oliviero, B., et al. (2002). Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood, 100, 230-237.
49. Hayashi, T., Hideshima, T., Akiyama, M., Raje, N., Richardson, P., & Chauhan, D., et al. (2003). Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood, 102, 1435-1442.
50. Hakomori, S. (2003). Structure, organization, and function of glycosphingolipids in membrane. Current Opinion in Hematology, 10, 16-24.
51. Birkle, S., Zeng, G., Gao, L., Yu, R. K., & Aubry, J. (2003). Role of tumor-associated gangliosides in cancer progression. Biochimie, 85, 455-463.
52. Shurin, G. V., Shurin, M. R., Bykovskaia, S., Shogan, J., Lotze, M. T., & Barksdale, E. M., Jr. (2001). Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Research, 61, 363-369.
53. Peguet-Navarro, J., Sportouch, M., Popa, I., Berthier, O., Schmitt, D., & Portoukalian, J. (2003). Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. Journal of Immunology, 170, 3488-3494.
54. Sombroek, C., Stam, A., Masterson, A., Lougheed, S., Schakel, M., & Meijer, C., et al. (2002). Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. Journal of Immunology, 168, 4333-4343.
55. Yang, L., Yamagata, N., Yadav, R., Brandon, S., Courtney, R., & Morrow, J., et al. (2003). Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. Journal of Clinical Investigation, 111, 727-735.
56. Young, M., Wright, M., Coogan, M., Young, M., and Bagash, J. (1992). Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunol Immunother, 35, 14-18.
57. Alleva, D., Walker, T., & Elgert, K. (1995). Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: Contrasting effects on resting and activated macrophages. Journal of Leukocyte Biology, 57, 919-928.
58. Maeda, H., & Shiraishi, A. (1996). TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. Journal of Immunology, 156, 73-78.
59. Reeves, E., Lu, H., Jacobs, H., Messina, C., Bolsover, S., & Gabella, G., et al. (2002). Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature, 416, 291-297.
60. Schmielau, J., & Finn, O. J. (2001). Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Research, 61, 4756-4760.
61. Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004). Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. Journal of Immunology, 172, 989-999.
62. Sauer, H., Wartenberg, M., & Hescheler, J. (2001). Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cellular Physiology and Biochemistry, 11, 173-186.
63. Rane, S. G., & Reddy, E. S. (2000). Janus kinases: Components of multiple signaling pathways. Oncogene, 19, 5662-5679.
64. Imada, K. & Leonard, W. J. (2000). The JAK-STAT pathway. Molecular Immunology, 37, 1-11.
65. Nosaka, T., & Kitamura, T. (2000). Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells. International Journal of Hematology, 71, 309-319.
66. Steelman, L. S., Pohnert, S. C., Shelton, J. G., Franklin, R. A., Bertrand, F. E., & McCubrey, J. A. (2004). JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 18, 189-218.
67. Laouar, Y., Welte, T., Fu, X.-Y., & Flavell, R. A. (2003). STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity, 19, 903-912.
68. Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., & Zhang, S., et al. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Natural Medicines, 10, 48-54.